m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05352
 [1]
Non-coding RNA LNC942 METTL14  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CXCR4 CXCR4 METTL14 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target C-X-C chemokine receptor type 4 (CXCR4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long intergenic non-protein coding RNA 942 (LINC00942) LncRNA View Details
Regulated Target Methyltransferase-like protein 14 (METTL14) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary LINC00942 directly recruits METTL14 protein by harboring the specific recognize sequence (+176-+265), thereby stabilized the expression of downstream targets of LNC942 including C-X-C chemokine receptor type 4 (CXCR4) and CYP1B1 through posttranscriptional m6A methylation modification in vitro and in vivo.
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Pathway Response Apoptosis hsa04210
Cell Process Cell apoptosis
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
C-X-C chemokine receptor type 4 (CXCR4) 61 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Plerixafor Approved [2]
Synonyms
Mozobil; AMD3100; Amd 3100; JM 2987; JM 3100; JM3100; SDZ SID 791; SID791; AMD-3100; Bicyclam JM-2987; JM-3100; Mozobil (TN); GNA & AMD-3100; HHA & AMD-3100; Plerixafor (INN/USAN); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane]; 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Galanthus nivalis agglutinin (GNA); 1,1'-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] & Hippeastrum hybrid agglutinin(HHA); 1,1'-{1,4-phenylenebis(methylene)}-bis{1,4,8,11-tetraaza-cyclotetradecane}; 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 0.057 ug.mL-1
External Link
CID: 65015
TTD: D0L5RW
DrugBank: DB06809
 Compound Name Motixafortide Approved [3]
MOA Antagonist
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Ulocuplumab Phase 3 [4]
MOA Antagonist
External Link
TTD: D0C3LQ
 Compound Name Balixafortide Phase 3 [5]
Synonyms
1051366-32-5; Balixafortide [INN]; UNII-PRC974M49B; PRC974M49B; Ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his cyclic (2->9)-disulfide; Cyclo(L-alanyl-L-cysteinyl-L-seryl-L-alanyl-D-prolyl-(2S)-2,4-diaminobutanoyl-L-arginyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-glutaminyl-L-lysyl-D-prolyl-L-prolyl-L-tyrosyl-L-histidyl), cyclic (2->9)-disulfide
    Click to Show/Hide
MOA Antagonist
External Link
CID: 91864511
TTD: D0GG9P
 Compound Name AMD-070 Phase 3 [6]
Synonyms
AMD 070; AMD070; AMD11070; S14-0353; N-(1H-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine; N'-(1H-Benzo[d]imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine Trihydrobromide Dihydrate
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 13 nM
External Link
CID: 11256587
TTD: D0O2XQ
DrugBank: DB05501
 Compound Name TG-0054 Phase 2 [7]
Synonyms
CXCR4 binding inhibitor/cell mobilizer (iv, stem cell transplant), TaiGen Biotechnology
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44479007
TTD: D06KGI
DrugBank: DB11970
 Compound Name POL-6326 Phase 2 [8]
Synonyms
CXCR4 antagonists, Polyphor; POL-2438; POL-3026; Epitope mimetics (HIV fusion), Polyphor; CXCR4 antagonists (cancer/HIV), Polyphor
    Click to Show/Hide
MOA Antagonist
External Link
TTD: D0FV8P
 Compound Name CTCE-9908 Phase 1/2 [9]
Synonyms
Anticancer therapy, Chemokine Therapeutics; CTCE-9908/0019
    Click to Show/Hide
MOA Modulator
External Link
CID: 16186350
TTD: D01TJM
 Compound Name USL311 Phase 1/2 [10]
Synonyms
Usl-311; UNII-2BTG5MX2Q2; 2BTG5MX2Q2; SCHEMBL15347153; 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-; 1373268-67-7
    Click to Show/Hide
MOA Antagonist
External Link
CID: 56961879
TTD: D08XQV
DrugBank: DB15265
 Compound Name ALX-0651 Phase 1 [11]
Synonyms
Anti-CXCR4 nanobodies (cancer), Ablynx
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D09MPD
 Compound Name CTCE-0214 Phase 1 [12]
Synonyms
CTCE-0013; CTCE-0021; CXCR4 agonists, Chemokine Therapeutics; Stem cell transplant therapy, Chemokine Therapeutics
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0AZ3Y
 Compound Name MSX-122 Phase 1 [13]
MOA Antagonist
External Link
CID: 11687907
TTD: D0E5JC
DrugBank: DB12715
 Compound Name PF-06747143 Phase 1 [4]
MOA Antagonist
External Link
TTD: D0LC5L
 Compound Name BMS-936564 Phase 1 [14]
MOA Modulator
External Link
TTD: D0Z8JR
 Compound Name LY2624587 Phase 1 [15]
MOA Antagonist
External Link
TTD: D3KZ6M
 Compound Name GMI-1359 Phase 1 [16]
MOA Antagonist
External Link
TTD: DBDW09
 Compound Name Garnocestim Discontinued in Phase 1 [17]
Synonyms
SB-251353
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0H5KK
 Compound Name SURADISTA Discontinued in Phase 1 [18]
Synonyms
PNU-145156E; FCE-26644 (formerly); PNU-151484 (Na salt); 7,7'-[Carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3-naphthalenedisulfonic acid tetrapotassium salt; 7,7-Ureylene-bis(1-methyl-4,2-pyrrolecarboxamido)bis(1-methyl-4,2-pyrrolecarboxamido)bis(1,3-naphthalenedisulfonic acid) tetrapotassium salt
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0I4OX
 Compound Name MAb173 Preclinical [19]
MOA Antagonist
External Link
TTD: D2NU0H
 Compound Name KRH-2731 Terminated [20]
MOA Binder
External Link
TTD: D00FJS
 Compound Name Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL436536
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 99 nM
External Link
CID: 44418888
TTD: D00GII
 Compound Name Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL375993
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 157 nM
External Link
CID: 44418891
TTD: D00XBM
 Compound Name Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL218806
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 44418892
TTD: D02UES
 Compound Name GSK-812397 Investigative [22]
Synonyms
CXCR4 receptor antagonists (HIV-1 infection); CXCR4 receptor antagonists (HIV-1 infection), GlaxoSmithKline
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 0.87 nM
External Link
CID: 11718722
TTD: D03QJA
 Compound Name AT-009 Investigative [22]
MOA Antagonist
External Link
TTD: D04ATE
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) Investigative [21]
Synonyms
CHEMBL426169
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 563 nM
External Link
CID: 44418894
TTD: D04BVW
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) Investigative [21]
Synonyms
CHEMBL387120
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 170 nM
External Link
CID: 44418872
TTD: D04PDF
 Compound Name Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL374421
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 23 nM
External Link
CID: 44418887
TTD: D04TED
 Compound Name Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) Investigative [23]
Synonyms
Fc-131; FC131; CHEMBL436283; FC 131; 606968-52-9; CHEMBL2180076; AC1NQNK6; SCHEMBL15987252; ZINC3925712; Cyclo(-Nal-Gly-D-Tyr-Arg-Arg-); BDBM50399002; BDBM50166106; KB-272560; B7647; N-{3-[(2S,5S,8S,14R)-5-(3-Guanidino-propyl)-14-(4-hydroxy-benzyl)-8-naphthalen-2-ylmethyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-propyl}-guanidine
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 5275843
TTD: D04TIO
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) Investigative [21]
Synonyms
CHEMBL219135
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 350 nM
External Link
CID: 44418885
TTD: D04XHX
 Compound Name KUR-CXCR4 Investigative [22]
MOA Modulator
External Link
TTD: D05IXH
 Compound Name isothiourea-1t Investigative [24]
Synonyms
IT1t
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 8 nM
External Link
CID: 25147749
TTD: D05VQJ
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) Investigative [21]
Synonyms
CHEMBL374862
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 256 nM
External Link
CID: 44418895
TTD: D05YHT
 Compound Name CX-02 Investigative [22]
Synonyms
CX-05; CXCR4 monoclonal antibodies (cancer); CXCR4 monoclonal antibodies (cancer), Northwest Biotherapeutics; CXCR4 therapeutics (cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D06EBJ
 Compound Name isothiourea-1a Investigative [24]
Synonyms
IT1a
    Click to Show/Hide
MOA Antagonist
Activity IC50 = 11 nM
External Link
CID: 11176403
TTD: D06MBD
 Compound Name ND-401 Investigative [22]
Synonyms
ND-4019; CCR5 and CXCR4 inhibitors (HIV infection), NeED Pharmaceuticals
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07IZP
 Compound Name CXCR4 gene disrupted T cells Investigative [22]
Synonyms
CXCR4 gene disrupted T cells (HIV infection)
    Click to Show/Hide
MOA Modulator
External Link
TTD: D07VDF
 Compound Name T134 Investigative [25]
Synonyms
GTPL852
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16197445
TTD: D08NJD
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) Investigative [21]
Synonyms
CHEMBL219075
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 167 nM
External Link
CID: 44418890
TTD: D08XRM
 Compound Name Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL376219
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 21 nM
External Link
CID: 44418893
TTD: D08YYV
 Compound Name ATI-2341 Investigative [22]
Synonyms
ATI-2346; ATI-2756; ATI-2766; CXCR4 agonists (cancer/bone marrow transplantation), Ascent; Pepducins (cancer/bone marrow transplantation), Ascent
    Click to Show/Hide
MOA Agonist
External Link
CID: 121513892
TTD: D0A7GH
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) Investigative [21]
Synonyms
CHEMBL375850
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 250 nM
External Link
CID: 44418889
TTD: D0B8VW
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) Investigative [21]
Synonyms
CHEMBL376811
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 92 nM
External Link
CID: 44418879
TTD: D0BH8K
 Compound Name Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL384429
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 230 nM
External Link
CID: 44418869
TTD: D0FQ3G
 Compound Name T140 Investigative [25]
Synonyms
[L-3-(2-naphthyl)-alanine3]-T134
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16130395
TTD: D0I6AN
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) Investigative [21]
Synonyms
CHEMBL373636
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11 nM
External Link
CID: 44418880
TTD: D0K0SO
 Compound Name Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL373440
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 130 nM
External Link
CID: 44418868
TTD: D0K9KQ
 Compound Name CTCE-0324 Investigative [22]
Synonyms
Vascular disease therapeutic, Chemokine Therapeutics
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0L3GH
 Compound Name Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL374108
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 63 nM
External Link
CID: 44418865
TTD: D0M6RQ
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) Investigative [21]
Synonyms
CHEMBL375991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 47 nM
External Link
CID: 44418878
TTD: D0P7UV
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL219474
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 11158428
TTD: D0Q3MM
 Compound Name LP-0067 Investigative [22]
Synonyms
CXCR4 antagonists (autoimmune disease); CXCR4 antagonists (autoimmune disease), Leo Pharma
    Click to Show/Hide
MOA Antagonist
External Link
TTD: D0Q7XS
 Compound Name NB-325 Investigative [22]
Synonyms
PEHMB; Polyethylene hexamethylene biguanide
    Click to Show/Hide
MOA Modulator
External Link
CID: 15954275
TTD: D0R4WT
 Compound Name Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL219096
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 128 nM
External Link
CID: 44418886
TTD: D0S0GV
 Compound Name Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) Investigative [21]
Synonyms
CHEMBL375990
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 11 nM
External Link
CID: 44418873
TTD: D0S0PU
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) Investigative [21]
Synonyms
CHEMBL373637
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 640 nM
External Link
CID: 44418883
TTD: D0ST1U
 Compound Name T22 Investigative [25]
Synonyms
[Tyr5,12,Lys7]-polyphemusin II
    Click to Show/Hide
MOA Antagonist
External Link
CID: 16197316
TTD: D0TL6C
 Compound Name TN-14003 Investigative [26]
Synonyms
UNII-1TW3FT746I; 1TW3FT746I; TN14003; BDBM194584; US9205085, MSX-207; H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2; L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4->13)-disulfide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16130647
TTD: D0Y3OX
 Compound Name Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) Investigative [21]
Synonyms
CHEMBL219339
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
CID: 11331592
TTD: D0ZO3C
 Compound Name CXCL8 Investigative [27]
Synonyms
Interleukin-8; CHEMBL411250; IL-8
    Click to Show/Hide
MOA Agonist
External Link
CID: 74974005
TTD: D07PHS
 Compound Name viral macrophage inflammatory protein-II Investigative [28]
Synonyms
CFLTKRGRQVC; vMIP-II; AC1LAF0N; GTPL768; vMIP-II (RESIDUE 41-51, CYCLIC); (4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-amino-22-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-31-benzyl-13,19-bis[3-(diaminomethylideneamino)propyl]-25-[(1R)-1-hydroxyethyl]-28-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacontane-4-carboxylic acid
    Click to Show/Hide
MOA Antagonist
External Link
CID: 486830
TTD: D09PZD
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [29]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [30]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 3 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 6 Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. doi: 10.1097/QAI.0b013e3181627566.
Ref 7 CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28. doi: 10.3727/096368914X681739. Epub 2014 May 12.
Ref 8 CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64. doi: 10.2174/157489212801820039.
Ref 9 A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6. doi: 10.1016/j.jss.2008.06.044. Epub 2008 Aug 9.
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
Ref 12 Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. doi: 10.1007/s10753-011-9297-5.
Ref 13 Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85. doi: 10.1189/jlb.1202613. Epub 2003 Nov 3.
Ref 14 BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. doi: 10.1158/1078-0432.CCR-12-2333. Epub 2012 Dec 4.
Ref 15 Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585. doi: 10.1371/journal.pone.0150585. eCollection 2016.
Ref 16 Clinical pipeline report, company report or official report of GlycoMimetics.
Ref 17 CN patent application no. 101094684, With the combination of chemokine activation progenitor cells/stem cells.
Ref 18 Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002 Dec;8(12):3955-60.
Ref 19 Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology. 2000 Mar 15;268(2):329-44. doi: 10.1006/viro.1999.0151.
Ref 20 Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. doi: 10.1016/S1359-6446(05)03550-6.
Ref 21 Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities. J Med Chem. 2007 Jan 25;50(2):192-8. doi: 10.1021/jm0607350.
Ref 22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
Ref 23 Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9. doi: 10.1016/j.bmcl.2008.05.092. Epub 2008 May 29.
Ref 24 Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20. doi: 10.1021/jm801065q.
Ref 25 A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. doi: 10.1006/bbrc.1998.9871.
Ref 26 Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64. doi: 10.1021/jm070679i. Epub 2007 Oct 24.
Ref 27 Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. doi: 10.1073/pnas.0402090101. Epub 2004 Jul 28.
Ref 28 A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. doi: 10.1126/science.277.5332.1656.
Ref 29 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 30 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015